

Soliris Order Form (eculizumab)

FAX TO: 817-472-7213

PATIENT INFORMATION					
Patient Name: DOB:	Phone:	Sex:	M F Ht:	Wt: lbs kg	
Primary Language:Allergies:					
Patient Preferred Location:					
<icd 10="" code="" required=""> DIAGNOSIS & CLINICAL INFORMATION</icd>					
D59.3 Hemolytic Uremic Syndrome G70.0 D59.4 Other Non-Autoimmune Hemolytic Anemias Exace (Including Microangiopathic Hemolyticanemia) G70.0 D59.5 Paroxysmal Nocturnal Hemoglobinuria Exace	Neuromyelitis Optica O Generalized Myasthenia Gravis, w/o Acute erbation 1 Generalized Myasthenia Gravis, w/Acute erbation 1 Generalized Myasthenia Gravis, w/Acute erbation 1 Generalized Myasthenia Gravis, w/Acute erbation				
<u>REQUIRED</u> : Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy. <u>LAB RESULTS:</u> Include labs to support diagnosis.					
PRESCRIPTION					
		SOLIRIS	DILUENT VOLUME	FINAL VOLUME	
		300 mg	30 mL	60 mL	
SOLIRIS (eculizumab) Administer over at least 35 minutes in adults, not to exceed 2 hours.		600 mg	60 mL	120 mL	
PAROXUSMAL NOCTURNAL HEMOGLOBINURIA (PNH)	Pre-Medications	900 mg	90 mL	180 mL	
Loading Dose	Acetaminophen: 650 mg PO	1200 mg	120 mL	240 mL	
IV: Infuse 600 mg dose weekly for first 4 weeks followed by 900 mg dose at week 5 Maintenance Dose IV: Infuse 900 mg dose every 2 weeks for one year	Cetirizine: 10 mg PO Diphenhydramine: 25 mg PO Diphenhydramine: 25 mg IVP Other:	Required Labs Baseline Serum Lactage Dehydrogenase (LHD) Hemoglobin Level Documented Meningococcal Vaccine			
ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)	HEMOLYTIC UREMIC SYNDROME (aHUS) Pre-Medications Required Labs				
Loading Dose	Acetaminophen: 650 mg PO	 Baseline Serum Lactate Dehydrogenase (LHD) Hemoglobin Level Serum Creatinine/eGFR 			
IV: Infuse 900 mg dose weekly for first 4 weeks followed by 1200 mg dose at week 5	Cetirizine: 10 mg PO Diphenhydramine: 25 mg PO				
, Company of the comp	Diphenhydramine: 25 mg IVP		Platelet CountPlasma Exchange		
Maintenance Dose IV: Infuse 1200 mg dose every 2 weeks for one year	Other:	Documented Meninococcal Vaccine			
GENERALIZED MYASTHENIA GRAVIS (gMG) and NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) Loading Dose IV: Infuse 900 mg dose weekly for first 4 weeks followed by 1200 mg dose at week 5	Pre-Medications Acetaminophen: 650 mg PO Cetirizine: 10 mg PO Diphenhydramine: 25 mg PO Diphenhydramine: 25 mg IVP Other:	Required Labs Positive Serologic Test for Anti-AChR Antibodies Documented Meningococcal Vaccine Is the patient on any other disease modifying therapy? Yes No If yes, please note therapy and last dose:			
Maintenance Dose IV: Infuse 1200 mg dose every 2 weeks for one year		if ye	s, please note the	rapy and last dose:	
Post Treatment Observations: The patient is observed for 60 minut	utes following the first administration	ı.			
Adverse Events: In the event of an adverse reaction occurring at a	Medix Infusion suite, utilize the Medix	dix Infusion a	adverse reactions pr	rotocol.	
PRESCRIBER INFORMATION					
Prescriber Name:	Signature:				
Date: NPI #:	Specialty:				
Supervising Physician:				(If Applicable)	
ddress: City:			ate:	_ Zip:	
Contact Name: Phone:	Fax:	E	mail:		